Financial information

10-year financial record

Note

The results and adjusted earnings per share for the years 2016, 2017, 2018, 2019, 2020, 2021, 2022 and 2023 exclude certain items. These were:
− 2017 (£8.0m pre-tax gain), 2018 (£10.1m pre-tax gain), 2019 (£6.1m pre-tax gain), 2020 (£21.6m pre-tax loss), 2021 (£23.0m pre-tax gain) and 2022 (£8.3m pre-tax loss) and 2023 (£5.5m pre-tax gain) gains and losses from financial instruments not effective for cash flow hedging;
− 2020 (£23.8m loss), 2022 (£1.7m gain) and 2023 (£0.7m) restructuring costs;
− 2021 (£3.2m loss) and 2022 (£0.2m gain) third-party FSP costs;
− 2022 (£11.7m loss) UK defined benefit pension scheme past service cost;
− 2023 (£2.1m loss) US defined benefit pension scheme past service cost;
− 2024 (£nil);
− 2025 (£2.3m pre-tax loss) closure of Edinburgh research facility, (£2.1m pre-tax loss) closure of drug delivery business, (£4.9m pre-tax loss) other interest payable on historical and non-recurring tax matters. (£9.2m loss) on prior year adjustment taxation charge on historical and non-recurring tax matters and (£1.9m gain) taxation on adjusting items;
− 2026 (£14.9m pre-tax loss) cost reduction programme, (£2.0m pre-tax loss) loss of office payable to Executive Director, (£0.7m pre-tax loss) closure of drug delivery business, (£0.8m pre-tax gain) other interest payable on historical and non-recurring tax matters, (£5.4m gain) prior year adjustment taxation charge on historical and non-recurring tax matters, and (£3.7m gain) taxation on adjusting items.
The proposed dividend for FY2026 excludes the special dividend of 70.0p per share.